Biotechnologia Acta


  • Increase font size
  • Default font size
  • Decrease font size
Home Archive 2019 № 5 The use of herbal remedies in the treatment of hepatobiliary diseases: trends and prospects M. Gahramanova, M. Rudyk, L. Skivka
Print PDF

ISSN 2410-776X (Online)
ISSN 2410-7751 (Print)

Biotechnologia Acta, V. 12, No. 5, 2019
P. 42-62, Bibliography 173, English.
Universal Decimal Classification: 615.322:615.244


M. Gahramanova1,2, M. Rudyk2, L. Skivka2

1 Nargiz Medical Center, Baku, Azerbaijan
2 ESC “Institute of Biology and Medicine”, Taras Shevchenko National University of Kyiv, Ukraine

Hepatobiliary system diseases represent an important medical and social problem due to increasing morbidity rates worldwide. Liver and biliary diseases are characterized by complex pathophysiology as well as by multi- and comorbidity. The treatment of such diseases necessitates multitarget drug development. The effectiveness of current drugs in the treatment of hepatobiliary disorders remains low and the incidence of side-effects are profound. This actualizes the search and development of highly effective hepatoprotectors with a low incidence of side effects. Medicinal plants potentially constitute a sourse of such preparations. The review summarizes the data concerning mechanisms of hepatoprotective and immunomodulatory effects of medicinal plants and their phytoconstituents. The prospects for the development and use of herbal remedies in the treatment of hepatobiliary diseases are outlined.

Key words: hepatobiliary diseases, medicinal plants, hepatoprotectors, immunomodulators.

© Palladin Institute of Biochemistry of National Academy of Sciences of Ukraine, 2019

  • References
    • 1. Peery A. F., Crockett S. D., Murphy C. C., Lund J. L., Dellon E. S., Williams J. L., Jensen E. T., Shaheen N. J., Barritt A. S., Lieber S .R., Kochar B., Barnes E. L., Fan Y. C., Pate V., Galanko J., Baron T. H., Sandler R. S. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology. 2019, 156 (1), 254–272.e11.

      2. Pimpin L., Cortez-Pinto H., Negro F., Corbould E., Lazarus J. V., Webber L., Sheron N. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. J. Hepatol. 2018, 69 (3), 718–735.

      3. Das S., Mahakkanukrauh P., Ho C. C. The burden of gastrointestinal, liver, and pancreatic diseases: the global scenario. Gastroenterology. 2016, 150 (4), 1045–1046.

      4. Younossi Z., Henry L. Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality. Gastroenterology. 2016, 150 (8), 1778–1785.

      5. Rowe I. A. Lessons from epidemiology: the burden of liver disease. Dig. Dis. 2017, 35 (4), 304–309.

      6. Shmal'ko O. O. Development of composition and technology of phytosyrup of hepatoprotective and choleretic action. Ph.D. dissertation, Drug Tech., Pharm. Org. and For. Pharmacy. National University of Pharmacy. Kharkiv, Ukraine. 2017. (In Ukrainian).

      7. Skubyc'ka L. D., Severynovs'ka O. V. Complex analysis of blood parameters and acid-forming function of the stomach in diseases of the hepatobiliary system with concomitant pathologies. Visnyk Harkivs'kogo nacional'nogo universytetu imeni V.N.Karazina, Serija «Biologija». 2016, V. 27, P. 139–149. (In Ukrainian).

      8. Nedel's'ka S. M., Mazur V. I., Shumna T. Je. Diseases of the hepatobiliary system and pancreas in children: a textbook for students of the 6th year of medical faculty, interns, pediatricians, family doctors. Zaporizhzhja: [ZDMU]. 2017, 113 p. (In Ukrainian).

      9. Everhart J. E., Ruhl C. E. Burden of digestive diseases in the United States Part III: liver, biliary tract, and pancreas. Gastroenterology. 2009, 136 (4), 1134–1144.

      10. Resnetnyak V. I. Concept of pathogenesis and treatment of cholelithiasis. World J. Hepatol. 2012, 4 (2), 18–34.

      11. Ertel A. E., Bentrem D., Abbott D. E. Gall bladder cancer. Cancer Treat Res. 2016, V. 168, P. 101–120.

      12. Li X., Guo X., Ji H., Yu G., Gao P. Gallstones in patients with chronic liver diseases. Biomed. Res. Int. 2017, V. 2017, P. 9749802.

      13. Lammert F., Gurusamy K., Ko C. W., Miquel J. F., Méndez-Sánchez N., Portincasa P., van Erpecum K. J., van Laarhoven C. J., Wang D. Q. Gallstones. Nat. Rev. Dis. Primers. 2016, V. 2, P. 16024.

      14. EASL. Clinical practice guidelines: management of cholestatic liver diseases. Journal of Hepatology. 2009, 51 (2), 237–267.

      15. Mauss S. et al. Hepatology. Sydney: Flying Publisher. 2015, 655 p.

      16. Chekman I. S. Clinical pharmacology of hepatoprotectors. Lik. Sprava. 2001, V. 1, P. 15–19.

      17. Gasanova O. V., Sarkisova E. O., Chumak A. A., Ovsyannikova L. M., Nosach O. V., Alohina L. M., Gasanov V. A., Kryzhanivska V. V. Comparative characteristics of hepatoprotectors used for the treatment of non alcoholic steatohepatitis associated with herpesvirus infection in sufferers of the Chornobyl accident. Probl. Radiac. Med. Radiobiol. 2017, V. 22, P. 339–352.

      18. Somova M. N., Muzalevskaia E. N., Nikolaevskiĭ V. A., Buzlama A. V., Batishcheva G. A., Chernov Iu. N. Drug-induced liver damage and the problem of its pharmacological correction. Eksp. Klin. Farmakol. 2013, 76 (9), 38–43.

      19. Gu X., Manautou J. E. Molecular mechanisms underlying chemical liver injury. Expert Rev. Mol. Med. 2012, V. 14, P. e4.

      20. Kumar A. A review on hepatoprotective herbal drugs. IJRPC. 2012, 2 (1), 92–102.

      21. Kurkina A. V., Galyamova V. R., Kurkin V. A., Avdeeva E. V. Possibilities of phytotherapy at digestive system diseases. Pharmacy & Pharmacology. 2016, 2 (15), 26–40.

      22. Ali M., Khan T., Fatima K., Ali Q. U. A., Ovais M., Khalil A. T., Ullah I., Raza A., Shinwari Z. K., Idrees M. Selected hepatoprotective herbal medicines: Evidence from ethnomedicinal applications, animal models, and possible mechanism of actions. Phytother. Res. 2018, 32 (2), 199–215.

      23. Bedi O., Bijjem K. R. V., Kumar P., Gauttam V. Herbal induced hepatoprotection and hepatotoxicity: a critical review. Indian J. Physiol. Pharmacol. 2016, 60 (1), 6–21.

      24. Ilyas U., Katare D. P., Aeri V., Naseef P. P. A review of hepatoprotective and immunomodulatory herbal plants. Pharmacogn. Rev. 2016, 10 (19), 66–70.

      25. Enioutina E. Y., Salis E. R., Job K. M., Gubarev M. I., Krepkova L. V., Sherwin C. M. Herbal Medicines: challenges in the modern world. Part 5. status and current directions of complementary and alternative herbal medicine worldwide. Expert Rev. Clin. Pharmacol. 2017, 10 (3), 327–338.

      26. Treister-Goltzman Y., Peleg R. Trends in publications on complementary and alternative medicine in the medical literature. Journal of Complementary and Integrative Medicine. 2015, 12 (2), 111–115.

      27. Efferth T., Zacchino S., Georgiev M. I., Liu L., Wagner H., Panossian A. Nobel Prize for artemisinin brings phytotherapy into the spotlight. Phytomedicine. 2015, 22 (13), A1–A3.

      28. Hertweck C. Natural products as source of therapeutics against parasitic diseases. Angew. Chem. Int. Ed. Engl. 2015, 54 (49), 14622–14624.

      29. Sahoo N., Manchikanti P., Dey S. Herbal drugs: standards and regulation. Fitoterapia. 2010, 81 (6), 462–471.

      30. Zhang J., Wider B., Shang H., Li X., Ernst E. Quality of herbal medicines: challenges and solutions. Complement Ther. Med. 2012, 20 (1–2), 100–106.

      31. Govindaraghavan S., Sucher N. J. Quality assessment of medicinal herbs and their extracts: Criteria and prerequisites for consistent safety and efficacy of herbal medicines. Epilepsy Behav. 2015, 52 (Pt B), 363–371.

      32. Kolomojec' M. Ju., Vashenjak O. O. Comorbidity and polymorbidity in therapeutic practice. Ukrai'ns'kyj medychnyj chasopys. 2012, 5 (91), 140–143. (In Ukrainian).

      33. Tarlovskaya E. I. Comorbidity and polymorbidity – a modern interpretation and urgent tasks facing the therapeutic community. Kardiologiia. 2018, 58 (9), 29–38.

      34. Samorodskaja I. V., Bolotova E. V. Terminological and demographic aspects of comorbidity. Adv. Gerontol. 2016, 29 (3), 471–477.

      35. Jakovljević M., Ostojić L. Comorbidity and multimorbidity in medicine today: challenges and opportunities for bringing separated branches of medicine closer to each other. Psychiatr. Danub. 2013, 25 (1), 18–28.

      36. Meghani S. H., Buck H. G., Dickson V. V., Hammer M. J., Rabelo-Silva E. R., Clark R., Naylor M. D. The conceptualization and measurement of comorbidity: a review of the interprofessional discourse. Nurs. Res. Pract. 2013, V. 2013, P. 192782.

      37. Jepsen P. Comorbidity in cirrhosis. World J. Gastroenterol. 2014, 20 (23), 7223–7230.

      38. Scheen A. J. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications. Diabetes Metab. 2019, 45 (3), 213–223.

      39. Zhang Z. M., Liu Z., Liu L. M., Zhang C., Yu H. W., Wan B. J., Deng H., Zhu M. W., Liu Z. X., Wei W. P., Song M. M., Zhao Y. Therapeutic experience of 289 elderly patients with biliary diseases. World J. Gastroenterol. 2017, 23 (13), 2424–2434.

      40. Lawler E., Avila A. Alzheimer disease: monotherapy vs. combination therapy. Am. Fam. Physician. 2017, 95 (7), 452.

      41. Ohar J. A., Donohue J. F. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD. Semin. Respir. Crit. Care Med. 2010, 31 (3), 321–333.

      42. Zhou Z., Tang D. H., Xie J., Ayyagari R., Wu E., Niravath P. A. Systematic literature review of the impact of endocrine monotherapy and in combination with targeted therapy on quality of life of postmenopausal women with HR+/HER2-advanced breast cancer. Adv. Ther. 2017, 34 (12), 2566–2584.

      43. Zhang A., Sun H., Wang X. Potentiating therapeutic effects by enhancing synergism based on active constituents from traditional medicine. Phytother Res. 2014, 28 (4), 526–533.

      44. Liu J., Liu J., Shen F., Qin Z., Jiang M., Zhu J., Wang Z., Zhou J., Fu Y., Chen X., Huang C., Xiao W., Zheng C., Wang Y. Systems pharmacology analysis of synergy of TCM: an example using saffron formula. Sci. Rep. 2018, 8 (1), 380.

      45. Izzo A. A., Hoon-Kim S., Radhakrishnan R., Williamson E. M. A critical approach to evaluating clinical efficacy, adverse events and drug interactions of herbal remedies. Phytotherapy research. 2016, 30 (5), 691–700.

      46. Marignani M., Gallina S., Di Fonzo M., Deli I., Begini P., Gigante E., Epifani M., Angeletti S., Delle Fave G. Use and safety perception of herbal remedies in patients with liver/biliary tract disorders: an Italian study. J. Clin. Gastroenterol. 2010, 44 (1), S54–57.

      47. Sultana B., Yaqoob S., Zafar Z., Bhatti H. N. Escalation of liver malfunctioning: A step toward Herbal Awareness. J. Ethnopharmacol. 2018, V. 216, P. 104–119.

      48. Soleimani V., Delghandi P. S., Moallem S. A., Karimi G. Safety and toxicity of silymarin, the major constituent of milk thistle extract: An updated review. Phytother. Res. 2019, 33 (6), 1627–1638.

      49. Watychowicz K., Janda K., Jakubczyk K., Wolska J. Chaenomeles – health promoting benefits. Rocz. Panstw. Zakl. Hig. 2017, 68 (3), 217–227.

      50. Rjeibi I., Ben Saad A., Hfaiedh N. Oxidative damage and hepatotoxicity associated with deltamethrin in rats: The protective effects of Amaranthus spinosus seed extract. Biomed. Pharmacother. 2016, V. 84, P. 853–860.

      51. Ibadullayeva S., Gasimov H., Gahramanova M., Zulfugarova P., Novruzova L. Medico-Ethnobotanical Inventory (Liver and Gallbladder Ducts Illnesses) of Nakhchivan AR, Azerbaijan. International Journal of Sciences. 2015, 1 (06), 80–88.

      52. Gahramanova M., Dovhyi R., Rudyk M., Molozhava O., Svyatetska V., Skivka L. Phytochemical screening of polyherbal composition based on Portulaca oleracea and it’s effect on macrophage oxidative metabolism. Biotechnol. acta. 2019, 12 (2) 63–70.

      53. Zhang A., Sun H., Wang X. Recent advances in natural products from plants for treatment of liver diseases. Eur. J. Med. Chem. 2013, V. 63, P. 70–77.

      54. Bansal J., Kumar N., Malviya R., Sharma P. K. Hepatoprotective models and various natural product used in hepatoprotective agents: a review. Pharmacogn. Commun. 2014, V. 4, P. 1–30.

      55. Domitrovic R., Potocnjak I. A comprehensive overview of hepatoprotective natural compounds: mechanism of action and clinical perspectives. Arch. Toxicol. 2016, 90 (1), 39–79.

      56. Balasundram N., Sundram K., Samman S. Phenolic compounds in plants and agri-industrial by-products: antioxidant activity, occurrence, and potential uses. Food Chem. 2006, V. 99, P. 191–203.

      57. Manach C., Scalbert A., Morand C., Rémésy C., Jiménez L. Polyphenols: food sources and bioavailability. Am. J. Clin. Nutr. 2004, 79 (5), 727–747.

      58. Mohib M., Afnan K., Paran T. Z., Khan S., Sarker J., Hasan N., Hasan I., Sagor A. T. Beneficial role of citrus fruit polyphenols against hepatic dysfunctions: a review. J. Diet. Suppl. 2018, 15 (2), 223–250.

      59. Pereira C., Barros L., Ferreira I. C. Extraction, identification, fractionation and isolation of phenolic compounds in plants with hepatoprotective effects. J. Sci. Food Agric. 2016, 96 (4), 1068–1084.

      60. Kurkin V. A., Kurkina A. V., Avdeeva E. V. Flavonoids as biologically active compounds of medicinal plants. Fundamental'nye issledovanija. 2013, 11 (9), 1897–1901. (In Russian).

      61. Ghosh N., Ghosh R., Mandal V., Mandal S. C. Recent advances in herbal medicine for treatment of liver diseases. Pharm. Biol. 2011, 49 (9), 970–988.

      62. Federico A., Dallio M., Loguercio C. Silymarin/silybin and chronic liver disease: a marriage of many years. Molecules. 2017, 22 (2), pii: E191.

      63. Vovk E. I. Milk thistle in modern hepatology: the relay race of generations from Ancient Greece to nowadays. Rus. Med. zh. 2010, V. 30, P. 18–37. (In Russian).

      64. An Z., Qi Y. M., Huang D. J., Gu X., Tian Y., Li P., Li H., Zhang Y. EGCG inhibits Cd2+-induced apoptosis through scavenging ROS rather than chelating Cd2+ in HL-7702 cells. Toxicol. Mech. Method. 2014, 24 (4), 259–267.

      65. Zhang T. S., Kimura Y., Jiang S. Y., Harada K., Yamashita Y., Ashida H. Luteolin modulates expression of drug-metabolizing enzymes through the AhR and Nrf2 pathways in hepatic cells. Arch. Biochem. Biophys. 2014, V. 557, P. 36–46.

      66. Li S., Tan H. Y., Wang N., Cheung F., Hong M., Feng Y. The potential and action mechanism of polyphenols in the treatment of liver diseases. Oxid. Med. Cell Longev. 2018, V. 2018, P. 8394818.

      67. Sun X., Duan X., Wang C., Liu Z., Sun P., Huo X., Ma X., Sun H., Liu K., Meng Q. Protective effects of glycyrrhizic acid against non-alcoholic fatty liver disease in mice. Eur. J. Pharmacol. 2017, V. 806, P. 75–82.

      68. Sil R., Ray D., Chakraborti A. S. Glycyrrhizin ameliorates metabolic syndrome-induced liver damage in experimental rat model. Mol. Cell Biochem. 2015, 409 (1–2), 177–189.

      69. Xu G. B., Xiao Y. H., Zhang Q. Y., Zhou M., Liao S. G. Hepatoprotective natural triterpenoids. Eur. J. Med. Chem. 2018, V. 145, P. 691–716.

      70. Sánchez-Crisóstomo I., Fernández-Martínez E., Cariño-Cortés R., Betanzos-Cabrera G., Bobadilla-Lugo R. A. Phytosterols and triterpenoids for prevention and treatment of metabolic-related liver diseases and hepatocellular carcinoma. Curr. Pharm. Biotechnol. 2019, 20 (3), 197–214.

      71. Kandanur S. G. S., Tamang N., Golakoti N. R., Nanduri S. Andrographolide: A natural product template for the generation of structurally and biologically diverse diterpenes. Eur. J. Med. Chem. 2019, V. 176, P. 513–533.

      72. Tan W. S. D., Liao W., Zhou S., Wong W. S. F. Is there a future for andrographolide to be an anti-inflammatory drug? Deciphering its major mechanisms of action. Biochem. Pharmacol. 2017, V. 139, P. 71–81.

      73. Jia R., Du J. L., Cao L. P., Liu Y. J., Xu P., Yin G. J. Protective action of the phyllanthin against carbon tetrachloride-induced hepatocyte damage in Cyprinus carpio. In Vitro Cell. Dev. Biol. Anim. 2016, 52 (1), 1–9.

      74. Lu K. L., Wang L. N., Zhang D. D., Liu W. B., Xu W. N. Berberine attenuates oxidative stress and hepatocytes apoptosis via protecting mitochondria in blunt snout bream Megalobrama amblycephala fed high-fat diets. Fish Physiol. Biochem. 2017, 43 (1), 65–76.

      75. Neag M. A., Mocan A., Echeverría J., Pop R. M., Bocsan C. I., Crişan G., Buzoianu A. D. Berberine: botanical occurrence, traditional uses, extraction methods, and relevance in cardiovascular, metabolic, hepatic, and renal disorders. Front. Pharmacol. 2018, V. 9, P. 557.

      76. Chernyh V. P. Pharmaceutical encyclopedia. 2nd ed., revised and enlarged. National University of Pharmacy of Ukraine. Kyiv: Morion. 2010, 1632 p. (In Ukrainian).

      77. Glushchenko A., Vladymyrova I., Georgiyants V. The substantiation of the selection of medicinal plants and their rational application in diseases of the hepatobiliary system. ScienceRise. Pharmaceutical Science. 2018, V. 2, P. 9–16.

      78. Fifi A. C., Axelrod C. H., Chakraborty P., Saps M. Herbs and spices in the treatment of functional gastrointestinal disorders: a review of clinical trials. Nutrients. 2018, 10 (11), pii: E1715.

      79. Kelber O., Bauer R., Kubelka W. Phytptherapy in functional gastrointestinal disorders. Dig. Dis. 2017, V. 35, P. 36–42.

      80. Daniyal M., Akram M., Zainab R., Munir N., Sharif A., Shah S. M. A., Liu B., Wang W. Prevalence and current therapy in chronic liver disorders. Inflammopharmacology. 2019, 27 (2), 213–231.

      81. Verhelst X., Dias A. M., Colombel J. F., Vermeire S., Van Vlierberghe H., Callewaert N., Pinho S. S. Protein glycosylation as a diagnostic and prognostic marker of chronic inflammatory gastrointestinal and liver diseases. Gastroenterology. 2019, pii: S0016-5085(19)41451-0.

      82. Chen P., Wang Y. Y., Chen C., Guan J., Zhu H. H., Chen Z. The immunological roles in acute-on-chronic liver failure: An update. Hepatobiliary Pancreat. Dis. Int. 2019, 18 (5), 403–411.

      83. Martin-Mateos R., Alvarez-Mon M., Albillos A. Dysfunctional immune response in acute-on-chronic liver failure: it takes two to tango. Front. Immunol. 2019, V. 10, P. 973.

      84. Laleman W., Claria J., Van der Merwe S., Moreau R., Trebicka J. Systemic inflammation and acute-on-chronic liver failure: too much, not enough. Can. J. Gastroenterol. Hepatol. 2018, V. 2018, P. 1027152.

      85. Li S., Hong M., Tan H. Y., Wang N., Feng Y. Insights into the role and interdependence of oxidative stress and inflammation in liver diseases. Oxid. Med. Cell. Longev. 2016, V. 2016, P. 4234061.

      86. Das S. K., DesAulniers J., Dyck J. R., Kassiri Z., Oudit G. Y. Resveratrol mediates therapeutic hepatic effects in acquired and genetic murine models of iron-overload. Liver Int. 2016, 36 (2), 246–257.

      87. Jiang S. L., Hu X. D., Liu P. Immunomodulation and liver protection of Yinchenhao decoction against concanavalin A-induced chronic liver injury in mice. J. Integr. Med. 2015, 13 (4), 262–268.

      88. Simon A. K., Hollander G. A., McMichael A. Evolution of the immune system in humans from infancy to old age. Proc. Biol. Sci. 2015, 282 (1821), 20143085.

      89. Scully, Georgakopoulou E. A., Hassona Y. The immune system: basis of so much health and disease: 3. Adaptive Immunity. Dent. Update. 2017, 44 (4), 322–324, 327.

      90. Ganeshan K., Chawla A. Metabolic regulation of immune responses. Annu. Rev. Immunol. 2014, V. 32, P. 609–634.

      91. Baraya Y. S., Wong K. K., Yaacob N. S. The immunomodulatory potential of selected bioactive plant-based compounds in breast cancer: a review. Anticancer Agents Med. Chem. 2017, 17 (6), 770–783.

      92. Akram M., Hamid A., Khalil A., Ghaffar A., Tayyaba N., Saeed A., Ali M., Naveed A. Review on medicinal uses, pharmacological, phytochemistry and immunomodulatory activity of plants. Int. J. Immunopathol. Pharmacol. 2014, 27 (3), 313–319.

      93. Singh R. K. Tinospora cordifolia as an adjuvant drug in the treatment of hyper-reactive malarious splenomegaly – case reports. J. Vect. Borne. Dis. 2005, V. 3, P. 36–38.

      94. Dhama K., Latheef S. K., Mani S., Samad H., Karthik A. K., Tiwari R., Khan R. U. Multiple beneficial applications and modes of action of herbs in poultry health and production-A review. Inter. J. Pharmacol. 2015, 11 (3), 152–176.

      95. Wagner H. K. M. Immunostimulants and Adaptogens from Plants. In: Recent Advances in Phytochemistry. Arnason J. T., Mata R., Romeo J. T. (eds). Boston: Springer. 1995, P. 1–18.

      96. Kumar D., Arya V., Kaur R., Bhat Z. A., Gupta V. K., Kumar V. A review of immunomodulators in the Indian traditional healthcare system. J. Microbiol. Immunol. Infect. 2012, 45 (3), 165–184.

      97. Massa S., Franconi R. Plant genes and plants proteins as adjuvants in cancer vaccination. Medicinal and Aromatic Plant Science and Biotechnology. 2012, 6 (special issue 2), 1–9.

      98. Sander V. A., Corigliano M. G., Clemente M. Promising plant-derived adjuvants in the development of coccidial vaccines. Front. Vet. Sci. 2019, V. 6, P. 20.

      99. Massa S., Paolini F., Curzio G., Cordeiro M. N., Illiano E., Demurtas O. C., Franconi R., Venuti A. A plant protein signal sequence improved humoral immune response to HPV prophylactic and therapeutic DNA vaccines. Hum. Vaccin Immunother. 2017, 13 (2), 271–282.

      100. Illiano E., Demurtas O. C., Massa S., Di Bonito P., Consalvi V., Chiaraluce R., Zanotto C., De Giuli Morghen C., Radaelli A., Venuti A., Franconi R. Production of functional, stable, unmutated recombinant human papillomavirus E6 oncoprotein: implications for HPV-tumor diagnosis and therapy. J. Transl. Med. 2016, 14 (1), 224.

      101. Shah S. A., Sander S., White C. M., Rinaldi M., Coleman C. I. Evaluation of echinacea for the prevention and treatment of the common cold: a meta-analysis. Lancet. Infect. Dis. 2007, 7 (7), 73–80.

      102. Haria E. N., Perera M. A. D. N., Senchina D. S. Immunomodulatory effects of Echinacea laevigata ethanol tinctures produced from different organs. Bioscience Horizons: The International Journal of Student Research. 2016, V. 9, P. hzw001.

      103. Li Y., Wang Y., Wu Y., Wang B., Chen X., Xu X., Chen H., Li W., Xu X. Echinacea pupurea extracts promote murine dendritic cell maturation by activation of JNK, p38 MAPK and NF-κB pathways. Dev. Comp. Immunol. 2017, V. 73, P. 21–26.

      104. EL-mahmood M. A. Efficacy of crude extracts of garlic (Allium sativum Linn) against nosocomial Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniea and Pseudomonas aeruginosa. J. Med. Plants Res. 2009, V. 3, P. 179–185.

      105. Weber N. D., Andersen D. O., North J. A., Murray B. K., Lawson L. D., Hughes B. G. In vitro virucidal effects of Allium sativum (garlic) extract and compounds. Planta. Med. 1992, 58 (2), 417–423.

      106. Mikaili P., Maadirad S., Moloudizargari M., Aghajanshakeri S., Sarahroodi S. Therapeutic uses and pharmacological properties of Garlic, Shallot, and their biologically active compounds. Iran. J. Basic Med. Sci. 2013, 16 (10), 1031–1048.

      107. Lee J. S., Lee Y., Lee Y., Hwang H. S., Kim K., Ko E., Kim M., Kang S. Ginseng protects against respiratory syncytial virus by modulating multiple immune cells and inhibiting viral replication. Nutrients. 2015, 7 (2), 1021–1036.

      108. Quan F. S., Compans R. W., Cho Y. K., Kang S. M. Ginseng and Salviae herbs play a role as immune activators and modulate immune responses during influenza virus infection. Vaccine. 2007, V. 25, P. 272–282.

      109. Sakure S., Negi V. D., Mitra S. K., Nandakumar K. S., Chakravortty D. Vaccine with herbal adjuvant—a better cocktail to combat the infection. Vaccine. 2008, 26 (2008), 3387–3388.

      110. Ulbricht C., Basch E., Cheung L., Goldberg H., Hammerness P., Isaac R., Khalsa K. P., Romm A., Rychlik I., Varghese M., Weissner W., Windsor R. C., Wortley J. An evidence-based systematic review of Elderberry and Elderflower (Sambucus nigra) by the natural standard research collaboration. J. Diet. Suppl. 2014, 11 (1), 80–120.

      111. Okonkwo C., Oladele O., Nwiyi P. The pattern of immunomodulation of ImmuPlus on the Infectious Bursal Disease (IBD) antibody of vaccinated broiler chickens. J. Vet. Adv. 2015, 5 (1), 808–813.

      112. Kumar K. M., Ramaiah S. Pharmacological importance of Echinacea Purpurea. Int. J. Pharma. Bio. Sci. 2011, 2 (4), 304–314.

      113. Janeway C. A. Jr., Travers P., Walport M., Shlomchik M. J. Immunobiology: The Immune System in Health and Disease: 5th edition. NY: Garland Publishing. 2001, 884 p.

      114. Tisoncik J. R., Korth M. J., Simmons C. P., Farrar J., Martin T. R., Katze M. G. Into the eye of the cytokine storm. Microbiol. Mol. Biol. Rev. 2012, 76 (1), 16–32.

      115. Liu Q., Zhou Y. H., Yang Z. Q. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell. Mol. Immunol. 2016, 13 (1), 3–10.

      116. Wheatley D. Stress-induced insomnia treated with kava and valerian: singly and in combination. Hum. Psychopharmacol. 2001, 16 (4), 353–356.

      117. Scholey A. B., Kennedy D. O. Acute, dose-dependent cognitive effects of Ginkgo biloba, Panax ginseng and their combinationin healthy young volunteers: differential interactions with cognitie demand. Hum. Psychopharmacol. 2002, 17 (1), 35–44.

      118. Gupta V. K., Fatima A., Faridi U., Negi A. S., Shanker K., Kumar J. K., Rahuja N., Luqman S., Sisodia B. S., Saikia D., Darokar M. P., Khanuja S. P. Antimicrobial potential of Glycyrrhiza glabra roots. J. Ethnopharmacol. 2008, 116 (2), 377–380.

      119. Guo A., He D., Xu H., Geng C., Zhao J. Promotion of regulatory T cell induction by immunomodulatory herbal medicine licorice and its two constituents. Scient. Rep. 2016, V. 5, P. 14046.

      120. Balaji B., Chempakam B. Pharmacokinetics prediction and drugability assessment of diphenyl-heptanoids from turmeric (Curcuma longa L). Med. Chem. 2015, 5 (2), 130–138.

      121. Grant K. L., Lutz R. B. Ginger. Am. J. Health-Syst. Pharm. 2000, 57 (10), 945–947.

      122. Hajhashemi V., Ghannadi A., Jafarabadi H. Black cumin seed essential oil, as a potent analgesic and antiinflammatory drug. Phytother. Res. 2004, 18 (3), 195–199.

      123. Jantan I., Ahmad W., Bukhari S. N. A. Corrigendum: Plant-derived immunomodulators:an insight on their preclinical evaluation and clinical trials. Front. Plant. Sci. 2018, V. 9, P. 1178.

      124. Hollman P. C. H. Evidence for health benefits of plant phenols: local or systemic effects? J. Sci. Food Agric. 2001, V. 81, P. 842–852.

      125. Ma Y., Kosińska-Cagnazzo A., Kerr W. L., Amarowicz R., Swanson R. B., Pegg R. B. Separation and characterization of soluble esterified and glycoside-bound phenolic compounds in dry-blanched peanut skins by liquid chromatography–electrospray ionization mass spectrometry. J. Agric. Food Chem. 2014, 62 (47), 11488–11504.

      126. Pandey K. B., Rizvi S. I. Plant polyphenols as dietary antioxidants in human health and disease. Oxid. Med. Cell. Longev. 2009, 2 (5), 270–278.

      127. Ding S., Jiang H., Fang J. Regulation of immune function by polyphenols. J. Immunol. Res. 2018, V. 2018, P. 1264074.

      128. Magrone T., Kumazawa Y., Jirillo E. Polyphenol-mediated beneficial effects in healthy status and disease with special reference to immune-based mechanisms. Polyphenols in Human Health and Disease. 2014, V. 1, P. 467–479.

      129. Zhu D., Ma Y., Ding S., Jiang H., Fang J. Effects of melatonin on intestinal microbiota and oxidative stress in colitis mice. Biomed. Res. Int. 2018, V. 2018, P. 2607679.

      130. Tachibana H. Green tea polyphenol sensing. Proc. Jpn. Acad. Ser. B. Phys. Biol. Sci. 2011, 87 (3), 66–80.

      131. Sprangers S., de Vries T. J., Everts V. Monocyte heterogeneity: consequences for monocyte-derived immune cells. J. Immunol. Res. 2016, V. 2016, P. 1475435.

      132. Yang C. S., Wang X. Green tea and cancer prevention. Nutr. Cancer. 2010, 62 (7), 931–937.

      133. Arce-Sillas A., Álvarez-Luquín D. D., Tamaya-Domínguez B., Gomez-Fuentes S., Trejo-García A., Melo-Salas M., Cárdenas G., Rodríguez-Ramírez J., Adalid-Peralta L. Regulatory T cells: molecular actions on effector cells in immune regulation. J. Immunol. Res. 2016, V. 2016, P. 1720827.

      134. Ranjith-Kumar C. T., Lai Y., Sarisky R. T., Cheng Kao C. Green tea catechin, epigallocatechin gallate, suppresses signaling by the dsRNA innate immune receptor RIG-I. PLoS One. 2010, 5 (9), e12878.

      135. Gong S. Q., Sun W., Wang M., Fu Y. Y. Role of TLR4 and TCR or BCR against baicalin-induced responses in T and B cells. Int. Immunopharmacol. 2011, 11 (12), 2176–2180.

      136. Guo T. L., Chi R. P., Zhang X. L., Musgrove D. L., Weis C., Germolec D. R., White K. L. Jr. Modulation of immune response following dietary genistein exposure in F0 and F1 generations of C57BL/6 mice: evidence of thymic regulation. Food Chem. Toxicol. 2006, 44 (3), 316–325.

      137. Yum M., Jung M., Cho D., Kim T. Suppression of dendritic cells’ maturation and functions by daidzein, a phytoestrogen. Toxicol. Appl. Pharmacol. 2011, 257 (2), 174–181.

      138. Kim M., Kim H., Park H., Kim D., Chung H., Lee J. Baicalin from Scutellaria baicalensis impairs Th1 polarization through inhibition of dendritic cell maturation. J. Pharmacol. Sci. 2013, 121 (2), 148–156.  10.1254/jphs.12200FP

      139. Yoshimura M., Akiyama H., Kondo K., Sakata K., Matsuoka H., Amakura Y., Teshima R., Yoshida T. Immunological effects of oenothein B, an ellagitannin dimer, on dendritic cells. Int. J. Mol. Sci. 2012, 14 (1), 46–56.

      140. Ramstead A., Schepetkin I., Quinn M., Jutila M. Oenothein B, a cyclic dimeric ellagitannin isolated from Epilobium angustifolium, enhances IFNγ production by lymphocytes. PloS One. 2012, 7 (11), e50546.

      141. Ramstead A., Schepetkin I., Todd K., Loeffelholz J., Berardinelli J., Quinn M., Jutila M. Aging influences the response of T cells to stimulation by the ellagitannin, oenothein B. Int Immunopharmacol. 2015, 26 (2), 367–377.

      142. Abd-Alla H., Moharram F., Gaara A., El-Safty M. Phytoconstituents of Jatropha curcas L. leaves and their immunomodulatory activity on humoral and cell-mediated immune response in chicks. Z. Naturforsch C. 2009, 64 (7–8), 495–501.

      143. Kumazawa Y., Takimoto H., Matsumoto T., Kawaguchi K. Potential use of dietary natural products, especially polyphenols, for improving type-1 allergic symptoms. Curr. Pharm. Des. 2014, 20 (6), 857–863.

      144. Magrone T., Tafaro A., Jirillo F., Amati L., Jirillo E., Covelli V. Elicitation of immune responsiveness against antigenic challenge in age-related diseases: effects of red wine polyphenols. Curr. Pharm. Des. 2008, 14 (26), 2749–2757.

      145. Yin Y., Sun Y., Gu L., Zheng W., Gong F., Wu X., Shen Y., Xu Q. Jaceosidin inhibits contact hypersensitivity in mice via down-regulating IFN-γ/STAT1/T-bet signaling in T cells. Eur. J. Pharmacol. 2011, 651 (1–3), 205–211.

      146. Sun Y., Wu X., Yin Y., Gong F., Shen Y., Cai T., Zhou X., Wu X., Xu Q. Novel immunomodulatory properties of cirsilineol through selective inhibition of IFN-gamma signaling in a murine model of inflammatory bowel disease. Biochem. Pharmacol. 2010, 79 (2), 229–238.

      147. Xiao J., Zhai H., Yao Y., Wang C., Jiang W., Zhang C., Simard A., Zhang R., Hao J. Chrysin attenuates experimental autoimmune neuritis by suppressing immuno-inflammatory responses. Neuroscience. 2014, V. 262, P. 156–164.

      148. Zhang X., Wang G., Gurley E., Zhou H. Flavonoid apigenin inhibits lipopolysaccharideinduced inflammatory response through multiple mechanisms in macrophages. PloS One. 2014, 9 (9), e107072.

      149. Liu Z., Zhong J., Gao E., Yang H. Effects of glycyrrhizin acid and licorice flavonoids on LPS-induced cytokines expression in macrophage. Zhongguo Zhong Yao Za Zhi. 2014, 39 (19), 3841–3845.

      150. Cho Y., You S., Kim H., Cho C., Lee I., Kang B. Xanthohumol inhibits IL-12 production and reduces chronic allergic contact dermatitis. Int. Immunopharmacol. 2010, 10 (5), 556–561.

      151. Yasui M., Matsushima M., Omura A., Mori K., Ogasawara N., Kodera Y., Shiga M., Ito K., Kojima S., Kawabe T. The suppressive effect of quercetin on toll-like receptor 7-mediated activation in alveolar macrophages. Pharmacology. 2015, 96 (5–6), 201–209.

      152. Wong C., Nguyen L., Noh S., Bray T., Bruno R., Ho E. Induction of regulatory T cells by green tea polyphenol EGCG. Immunol Lett. 2011, 139 (1–2), 7–13. imlet.2011.04.009

      153. Mossalayi M., Rambert J., Renouf E., Micouleau M., Mérillon J. Grape polyphenols and propolis mixture inhibits inflammatory mediator release from human leukocytes and reduces clinical scores in experimental arthritis. Phytomedicine. 2014, 21 (3), 290–297.

      154. Saroni Arwa P., Zeraik M. L., Ximenes V. F., da Fonseca L. M., Bolzani Vda S., Siqueira Silva D. H. Redox-active biflavonoids from Garcinia brasiliensis as inhibitors of neutrophil oxidative burst and human erythrocyte membrane damage. J. Ethnopharmacol. 2015, V. 174, P. 410–418.

      155. Chang M. C., Chang H. H., Wang T. M., Chan C. P., Lin B. R., Yeung S. Y., Yeh C. Y., Cheng R. H., Jeng J. H. Antiplatelet effect of catechol is related to inhibition of cyclooxygenase, reactive oxygen species, ERK/p38 signaling and thromboxane A2 production. PLoS One. 2014, 9 (8), e104310.

      156. Hopkins A. L. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 2008, 4 (11), 682–690.

      157. Boezio B., Audouze K., Ducrot P., Taboureau O. Network-based Approaches in Pharmacology. Mol. Inform. 2017, 36 (10).

      158. Zang W. J. Network pharmacology: A further description. Network Pharmacology. 2016, 1 (1), 1–14.

      159. Zhang G., Li Q., Chen Q., Su S. Network pharmacology: a new approach for chinese herbal medicine research. Evid. Based Complement. Alternat. Med. 2013, V. 2013, P. 621423.

      160. Di S., Han L., Wang Q., Liu X., Yang Y., Li F., ZhaoL., Tong X. A network pharmacology approach to uncover the mechanisms of Shen-Qi-Di-Huang decoction against diabetic nephropathy. Evid. Based Complement. Alternat. Med. 2018, V. 2018, P. 7043402.

      161. Van Vuuren S., Viljoen A. Plant-based antimicrobial studies--methods and approaches to study the interaction between natural products. Planta. Med. 2011, 77 (11), 1168–1182.

      162. Spinella M. The importance of pharmacological synergy in psychoactive herbal medicines. Altern. Med. Rev. 2002, 7 (2), 130–137.

      163. Williamson E. M. Synergy and other interactions in phytomedicines. Phytomedicine. 2001, 8 (5), 401–409.

      164. Efferth T., Koch E. Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Curr. Drug. Targets. 2011, 12 (1), 122–132.

      165. Malongane F., McGaw L. J., Mudau F. N. The synergistic potential of various teas, herbs and therapeutic drugs in health improvement: a review. J. Sci. Food Agric. 2017, 97 (14), 4679–4689.

      166. Bahmani M., Taherikalani M., Khaksarian M., Rafieian-Kopaei M., Ashrafi B., Nazer M., Soroush S., Abbasi N., Rashidipour M. The synergistic effect of hydroalcoholic extracts of Origanum vulgare, Hypericum perforatum and their active components carvacrol and hypericin against Staphylococcus aureus. Future Sci. OA. 2019, 5 (3), FSO371.

      167. Gadisa E., Weldearegay G., Desta K., Tsegaye G., Hailu S., Jote K., Takele A. Combined antibacterial effect of essential oils from three most commonly used Ethiopian traditional medicinal plants on multidrug resistant bacteria. BMC Complement. Altern. Med. 2019, 19 (1), 24.

      168. Su S., Hua Y., Wang Y., Gu W., Zhou W., Duan J. A., Jiang H., Chen T., Tang Y. Evaluation of the anti-inflammatory and analgesic properties of individual and combined extracts from Commiphora myrrha, and Boswellia carterii. J. Ethnopharmacol. 2012, 139 (2), 649–656.

      169. Gonulalan E. M., Nemutlu E., Demirezer L. O. A new perspective on evaluation of medicinal plant biological activities: The correlation between phytomics and matrix metalloproteinases activities of some medicinal plants. Saudi Pharm. J. 2019, 27 (3), 446–452.

      170. Gonulalan E. M., Nemutlu E., Bayazeid O., Koçak E., Yalçın F. N., Demirezer L. O. Metabolomics and proteomics profiles of some medicinal plants and correlation with BDNF activity. Phytomedicine. 2019, 152920.

      171. Yang Y., Zhang Z., Li S., Ye X., Li X., He K. Synergy effects of herb extracts: pharmacokinetics and pharmacodynamic basis. Fitoterapia. 2014, V. 92, P. 133–147.


Additional menu

Site search

Site navigation

Home Archive 2019 № 5 The use of herbal remedies in the treatment of hepatobiliary diseases: trends and prospects M. Gahramanova, M. Rudyk, L. Skivka

Invitation to cooperation

Dear colleagues, we invite you to publish your articles in our journal.
© Palladin Institute of Biochemistry of the National Academy of Sciences of Ukraine, 2008.
All rights are reserved. Complete or partial reprint of the journal is possible only with the written permission of the publisher.
for information: